Ferrocene-modified half-sandwich iridium(III) and ruthenium(II) propionylhydrazone complexes and anticancer application.
J Inorg Biochem
; 257: 112586, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38728860
ABSTRACT
Ferrocene, ruthenium(II) and iridium(III) organometallic complexes, potential substitutes for platinum-based drugs, have shown good application prospects in the field of cancer therapy. Therefore, in this paper, six ferrocene-modified half-sandwich ruthenium(II) and iridium(III) propionylhydrazone complexes were prepared, and the anticancer potential was evaluated and compared with cisplatin. These complexes showed potential in-vitro anti-proliferative activity against A549 cancer cells, especially for Ir-based complexes, and showing favorable synergistic anticancer effect. Meanwhile, these complexes showed little cytotoxicity and effective anti-migration activity. Ir3, the most active complex (ferrocene-appended iridium(III) complex), could accumulate in the intracellular mitochondria, disturb the cell cycle (S-phase), induce the accumulation of reactive oxygen species, and eventually cause the apoptosis of A549 cells. Then, the design of these complexes provides a good structural basis for the multi-active nonplatinum organometallic anticancer complexes.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ruthenium
/
Ferrous Compounds
/
Apoptosis
/
Coordination Complexes
/
Metallocenes
/
Hydrazones
/
Iridium
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
J Inorg Biochem
Year:
2024
Document type:
Article
Affiliation country: